|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: URGCP |
Gene summary for URGCP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | URGCP | Gene ID | 55665 |
| Gene name | upregulator of cell proliferation | |
| Gene Alias | URG4 | |
| Cytomap | 7p13 | |
| Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | Q8TCY9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55665 | URGCP | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.56e-11 | 3.54e-01 | 0.0155 |
| 55665 | URGCP | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.69e-17 | 7.31e-01 | -0.1808 |
| 55665 | URGCP | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.70e-11 | 5.89e-01 | -0.0811 |
| 55665 | URGCP | HTA11_78_2000001011 | Human | Colorectum | AD | 1.99e-23 | 7.58e-01 | -0.1088 |
| 55665 | URGCP | HTA11_347_2000001011 | Human | Colorectum | AD | 1.42e-29 | 8.21e-01 | -0.1954 |
| 55665 | URGCP | HTA11_411_2000001011 | Human | Colorectum | SER | 1.99e-12 | 1.15e+00 | -0.2602 |
| 55665 | URGCP | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.48e-07 | 8.41e-01 | -0.2196 |
| 55665 | URGCP | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.01e-08 | 4.97e-01 | -0.1207 |
| 55665 | URGCP | HTA11_83_2000001011 | Human | Colorectum | SER | 2.69e-09 | 5.17e-01 | -0.1526 |
| 55665 | URGCP | HTA11_696_2000001011 | Human | Colorectum | AD | 4.03e-19 | 6.33e-01 | -0.1464 |
| 55665 | URGCP | HTA11_866_2000001011 | Human | Colorectum | AD | 3.91e-14 | 4.99e-01 | -0.1001 |
| 55665 | URGCP | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.60e-22 | 8.38e-01 | -0.059 |
| 55665 | URGCP | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.31e-03 | 6.07e-01 | -0.1706 |
| 55665 | URGCP | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.43e-04 | 5.42e-01 | -0.2061 |
| 55665 | URGCP | HTA11_546_2000001011 | Human | Colorectum | AD | 1.48e-07 | 5.35e-01 | -0.0842 |
| 55665 | URGCP | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.82e-02 | 5.02e-01 | -0.00410000000000005 |
| 55665 | URGCP | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.05e-03 | 3.69e-01 | -0.0179 |
| 55665 | URGCP | HTA11_866_3004761011 | Human | Colorectum | AD | 6.39e-04 | 3.04e-01 | 0.096 |
| 55665 | URGCP | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.34e-03 | 5.36e-01 | 0.0446 |
| 55665 | URGCP | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.88e-03 | 4.98e-01 | 0.0528 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| URGCP | SNV | Missense_Mutation | c.2386N>G | p.Pro796Ala | p.P796A | Q8TCY9 | protein_coding | deleterious(0.04) | benign(0.318) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| URGCP | SNV | Missense_Mutation | c.1006N>T | p.Asn336Tyr | p.N336Y | Q8TCY9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| URGCP | SNV | Missense_Mutation | novel | c.1449C>G | p.Ile483Met | p.I483M | Q8TCY9 | protein_coding | deleterious(0.01) | probably_damaging(0.935) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| URGCP | SNV | Missense_Mutation | novel | c.799C>T | p.Arg267Cys | p.R267C | Q8TCY9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| URGCP | SNV | Missense_Mutation | novel | c.509C>A | p.Ser170Tyr | p.S170Y | Q8TCY9 | protein_coding | deleterious(0.04) | probably_damaging(0.924) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| URGCP | SNV | Missense_Mutation | c.1873N>A | p.Glu625Lys | p.E625K | Q8TCY9 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| URGCP | SNV | Missense_Mutation | c.1350N>A | p.Asp450Glu | p.D450E | Q8TCY9 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| URGCP | SNV | Missense_Mutation | c.2689G>A | p.Glu897Lys | p.E897K | Q8TCY9 | protein_coding | deleterious(0.04) | possibly_damaging(0.536) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| URGCP | SNV | Missense_Mutation | c.2689N>A | p.Glu897Lys | p.E897K | Q8TCY9 | protein_coding | deleterious(0.04) | possibly_damaging(0.536) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| URGCP | SNV | Missense_Mutation | c.2452N>C | p.Val818Leu | p.V818L | Q8TCY9 | protein_coding | deleterious(0.02) | possibly_damaging(0.705) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |